Grifols SA ADR is a drug manufacturers - general business based in the US. Grifols SA ADR shares (GRFS) are listed on the NASDAQ and all prices are listed in US Dollars. Grifols SA ADR employs 23,000 staff and has a trailing 12-month revenue of around $6.7 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $7.88 |
|---|---|
| 52-week range | $5.30 - $12.15 |
| 50-day moving average | $7.35 |
| 200-day moving average | $7.99 |
| Wall St. target price | $12.13 |
| PE ratio | 80.75 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.10 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.88 from 2024-07-22
| 1 week (2024-07-17) | -2.23% |
|---|---|
| 1 month (2024-06-24) | 9.60% |
| 3 months (2024-04-24) | 23.32% |
| 6 months (2024-01-24) | 2.87% |
| 1 year (2023-07-24) | -21.67% |
|---|---|
| 2 years (2022-07-22) | -25.38% |
| 3 years (2021-07-23) | 15.2 |
| 5 years (2019-07-24) | 21.4586 |
Valuing Grifols SA ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Grifols SA ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Grifols SA ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 81x. In other words, Grifols SA ADR shares trade at around 81x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Grifols SA ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2628. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Grifols SA ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Grifols SA ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.
The EBITDA is a measure of a Grifols SA ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $6.7 billion |
|---|---|
| Operating margin TTM | 14.88% |
| Gross profit TTM | $2.2 billion |
| Return on assets TTM | 2.3% |
| Return on equity TTM | 3.48% |
| Profit margin | 2.84% |
| Book value | $8.75 |
| Market Capitalization | $6.4 billion |
TTM: trailing 12 months
We're not expecting Grifols SA ADR to pay a dividend over the next 12 months.
Grifols SA ADR's shares were split on a 2:1 basis on 3 January 2016. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Grifols SA ADR shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Grifols SA ADR shares which in turn could have impacted Grifols SA ADR's share price.
Over the last 12 months, Grifols SA ADR's shares have ranged in value from as little as $5.3001 up to $12.1499. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Grifols SA ADR's is 0.672. This would suggest that Grifols SA ADR's shares are less volatile than average (for this exchange).
Grifols, S. A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development.
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.